Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22

Vasu S, Denlinger N, Song N, Elsberry D, Zhao Q, Yu L, Bezerra E, Szuminski N, Schneider D, Dash P, Wirthlin L, Epperla N, Sawalha Y, Woyach J, Nishat S, Rogers K, Bhat S, Ghoneim H, Behbehani G, Voorhees T, Larkin K, Kittai A, Churchill V, George E, Lamb M, Lee D, Chan W, Krull A, Orentas R, O’Donnell L, Li Z, Alinari L, de Lima M.

Open source

DOI: 10.21203/rs.3.rs-8605291/v1
Published: 2026-02-09
Container: Not recorded
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 39/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
cautionPublication version: Identified as a preprint; peer review and later versions may change the record. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.21203/rs.3.rs-8605291/v1,
  title = {Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22},
  author = {Vasu S and  Denlinger N and  Song N and  Elsberry D and  Zhao Q and  Yu L and  Bezerra E and  Szuminski N and  Schneider D and  Dash P and  Wirthlin L and  Epperla N and  Sawalha Y and  Woyach J and  Nishat S and  Rogers K and  Bhat S and  Ghoneim H and  Behbehani G and  Voorhees T and  Larkin K and  Kittai A and  Churchill V and  George E and  Lamb M and  Lee D and  Chan W and  Krull A and  Orentas R and  O’Donnell L and  Li Z and  Alinari L and  de Lima M.},
  year = {2026},
  doi = {10.21203/rs.3.rs-8605291/v1},
  url = {https://doi.org/10.21203/rs.3.rs-8605291/v1}
}

RIS

TY  - JOUR
TI  - Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22
AU  - Vasu S
AU  -  Denlinger N
AU  -  Song N
AU  -  Elsberry D
AU  -  Zhao Q
AU  -  Yu L
AU  -  Bezerra E
AU  -  Szuminski N
AU  -  Schneider D
AU  -  Dash P
AU  -  Wirthlin L
AU  -  Epperla N
AU  -  Sawalha Y
AU  -  Woyach J
AU  -  Nishat S
AU  -  Rogers K
AU  -  Bhat S
AU  -  Ghoneim H
AU  -  Behbehani G
AU  -  Voorhees T
AU  -  Larkin K
AU  -  Kittai A
AU  -  Churchill V
AU  -  George E
AU  -  Lamb M
AU  -  Lee D
AU  -  Chan W
AU  -  Krull A
AU  -  Orentas R
AU  -  O’Donnell L
AU  -  Li Z
AU  -  Alinari L
AU  -  de Lima M.
PY  - 2026
DO  - 10.21203/rs.3.rs-8605291/v1
UR  - https://doi.org/10.21203/rs.3.rs-8605291/v1
ER  -

APA

S, V., N, D., N, S., D, E., Q, Z., L, Y., E, B., N, S., D, S., P, D., L, W., N, E., Y, S., J, W., S, N., K, R., S, B., H, G., G, B., T, V., K, L., A, K., V, C., E, G., M, L., D, L., W, C., A, K., R, O., L, O., Z, L., L, A., & M., D. L. (2026). Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22. https://doi.org/10.21203/rs.3.rs-8605291/v1

Source records

europe-pmc · retrieved 2026-09-27T02:08:03.703Z